Pfizer Inc and BioNTech could secure emergency U.S. and European authorization for their coronavirus vaccine next month after final trial results showed it had a 95 percent success rate and no serious side effects, the drugmakers said. The final trial analysis comes a week after initial results showed the vaccine was more than 90 percent effective. The Moderna vaccine is likely to be authorized within seven to 10 days of Pfizer receiving its EUA, U.S. officials said, with states ready to begin distribution within 24 hours. Global shares rose as the trial results countered concerns around the soaring infection rate. Pfizer said vaccine was well-tolerated and that side effects were mostly mild to moderate, and cleared up quickly.

Source: The Standard November 19, 2020 02:58 UTC